ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO2301

Shrunken Pore Syndrome Is Associated with a Rise in Mortality in a Community-Based Population of Middle-Aged Individuals

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Xhakollari, Liana, Dept of Nephrology, Skåne University Hospital, Malmö, Skåne, Sweden
  • Åkesson, Anna, Dept of Clinical Sciences, Lund University, Malmö, Skåne, Sweden
  • Björk, Jonas, Dept of Clinical Sciences, Lund University, Malmö, Skåne, Sweden
  • Christensson, Anders, Dept of Nephrology, Skåne University Hospital, Malmö, Skåne, Sweden

Chronic kidney disease (CKD) is a risk factor for increased mortality mainly due to cardiovascular disease (CVD). Glomerular filtration rate (GFR) is the best way to estimate kidney function, but it cannot be measured. Creatinine and cystatin C are two molecules that are used in clinical practice to estimate GFR (eGFR). The lower eGFR, the higher is the mortality. CKD staging is therefore a good marker of mortality and development of CVD. However, there are patients who have the same CKD stage and risk factors for development of CVD but different outcome in mortality. Shrunken pore syndrome (SPS) has shown to be a marker of increased mortality in different patients groups regardless of their measured GFR. The theory behind SPS is supposed to be a difference in the renal filtration of small molecules like creatinine compared to middle sized molecules like cystatin C. Little is known about the prevalence of SPS and the effect on mortality in the general population. The aim of our study is to investigate this.


The study population consisted of 5061 individuals from the Malmö Diet and Cancer Cardiovascular cohort community-based study that was gathered during 1991 and 1996 in Malmö, Sweden. The individuals were 44-64 years old. Blood samples, anthropometric measurement and a questionnaire about life style etc was available. CAPACYC formula was used for eGFR based on cystatin C and LMRCR formula was used for eGFR based on creatinine. SPS was defined as eGFRCYS ≤ 70% of eGFRCR. Generalized propensity score was used to match individuals with SPS and those without. Kaplan–Meier estimates were used to present survival probabilities in four eGFRCYS/eGFRCR-ratio intervals. To account for within quartet correlation, or frailty, Cox proportional hazard models with shared frailty was employed. Results are presented as hazard ratios (HR) with 95 % confidence intervals (CI).


405 individuals (8%) fulfilled the criterion for SPS. Median (2.5-97.5 percentiles) eGFRcys was 63 (38-97) and median eGFRcr was 70 (49-92) mL/min/1.73m2. HR for mortality in individuals with SPS in the matched data was 2.43 (1.15 - 5.14).


Healthy middle age individuals with SPS have a doubled risk of all-cause mortality. Further studies are needed to explore the mechanisms behind the association between SPS and mortality.